PETROSCRAP.COM

Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States Silence Therapeutics plc (AIM: SLN) (“Silence” or the “Company”) announces the issuance of United States patent 7,723,316, titled Compositions and Methods of RNAi Therapeutics For Treatment of Cancer and Other Neovascularization Disease, by the United States Patent and Trademark Office (USPTO). The issued patent, which deepens the Company’s diverse portfolio of RNA interference (RNAi … Read more on SYS-CON…. Click Here to Read More

Silence Therapeutics to Present at Upcoming Investor Conferences Silence Therapeutics plc announces that Philip Haworth, Ph.D., chief executive officer, will present corporate updates at two upcoming industry and financial conferences. Â Dr. Haworth’s presentations will focus on Silence Therapeutics’ comprehensive RNA interference therapeutics platform, broad clinical-stage pipeline and multiple ongoing collaborations with leading pharmaceutical companies. Read more on PR Newswire via Yahoo!…. Click Here to Read More

Open house for Tri-Valley’s girls program Feb. 23 Seventh- and eighth-grade girls and their parents are invited to the seventh annual Reflections on Your Future event. The event is an introduction to a program designed to encourage girls to pursue interests in technology, science, math and engineering. Read more on Contra Costa Times ISA Technovation Awards 2010 announced BANGALORE, INDIA: At a gala award night here, India Semiconductor Association, the semiconductor-driven industry body of the country, on Monday announced Technovation Awards for the year 2010. Read more on CIOL EPO to grant patent notice to BioMimetic Therapeutics BioMimetic Therapeutics, Inc. announced…. Click Here to Read More